摘要
目的:探究替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2(HER-2)、中期因子(MK)水平的影响。方法:抽取2010年1月至2016年5月本院收治的64例乳腺癌患者,通过随机数表法分组,各32例。对照组采用三维适形放疗,研究组联合采用三维适形放疗+替吉奥胶囊,共治疗2个疗程。统计对比两组临床疗效、不良反应发生率,分析治疗前后两组肿瘤标志物[癌胚抗原(CEA)、CA125、CA153]及MK、HER-2水平变化情况。结果:研究组治疗有效率(50.00%)、肿瘤控制率(81.25%)高于对照组(25.00%、53.13%),差异有统计学意义(P<0.05);治疗前两组CEA、CA125、CA153水平对比差异无统计学意义(P>0.05),经治疗,两组各指标水平较治疗前降低,且研究组CEA、CA125、CA153水平均低于对照组,差异有统计学意义(P<0.05);治疗前两组HER-2及MK水平对比差异无统计学意义(P>0.05),经治疗,两组各指标水平较治疗前降低,且研究组HER-2及MK水平均低于对照组,差异有统计学意义(P<0.05);两组均未出现IV度不良反应,研究组白细胞减少、腹泻、呕吐恶心发生率(34.38%、34.38%、37.51%)与对照组(31.24%、37.51%、34.37%)对比,差异无统计学意义(P>0.05)。结论:替吉奥胶囊联合放疗治疗乳腺癌效果显著,可改善血清肿瘤标志物、HER-2及MK表达水平,且安全性较高,值得推广。
AIM：To explore the effect of gimeracil capsules combined with radiotherapy on breast cancer,and on tumor marker,human epidermal growth factor receptor-2（HER-2） and level of midkine（MK）.METHODS：Sixty-four breast cancer patients were selected by random number table method from January 2010 to May 2016 in our hospital,sixty-two cases in each group.The control group was treated with three-dimensional conformal radiotherapy;the study group was treated with three-dimensional conformal radiotherapy and gimeracil capsule;the therapy continued for 2 courses of treatment.Clinical efficacy and adverse reaction incidence rate were compared between two groups;tumor markers（CEA,CA125,CA153） and changes of MK,HER-2 level were analyzed.RESULTS：The effective rate（50%） and tumor control rate（81.25%） of the study group were higher than those of the control group（25%,53.13%）,the difference were statistically significant（P〈0.05）;Before treatment,no significant difference of CEA,CA125,CA153 was observed between groups（P〉0.05）,while all the indexes decreased after treatment,and the study group presented more significant change than the control group（P〈0.05）;Before treatment,no significant difference of HER-2 and MK level was observed between groups（P〉0.05）,while all the indexes decreased after treatment,and the study group presented more significant change than the control group（P〈0.05）.Both groups presented no IV degrees of adverse reactions,and compared with control group（31.24%,37.51%,34.37%）,the incidence of leucopenia,diarrhea,nausea and vomiting（34.38%,34.38%,37.51%） of the study group presented no statistically significance（P〉0.05）.CONCLUSION：Gimeracil capsules combined with radiotherapy exhibited remarkable effect on breast cancer,and on the serum tumor markers,human epidermal growth factor receptor-2 and midkine expression level.With high safety,it is worthy of promotion.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2017年第8期899-903,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
替吉奥胶囊
放疗
乳腺癌
肿瘤标志物
人类表皮生长因子受体-2
gimeracil capsules
radiotherapy
breast cancer
tumor marker
human epidermal growth factor receptor-2
